Lixte Biotechnology Holdings IncNASDAQ:LIXT
- LAST PRICE2.2400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.2000/ 1
- Ask / Lots2.5900/ 7
- Open / Previous Close0.0000 / 2.2400
- Day Range---
- 52 Week Range
- Volume147
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LIXT |
|---|---|---|
| 09:50 ET | 360 | 2.34 |
| 10:06 ET | 100 | 2.37 |
| 10:36 ET | 250 | 2.35 |
| 11:00 ET | 100 | 2.33 |
| 11:03 ET | 100 | 2.33 |
| 11:07 ET | 1067 | 2.31 |
| 11:14 ET | 200 | 2.29 |
| 11:16 ET | 500 | 2.28 |
| 11:18 ET | 3600 | 2.3 |
| 11:25 ET | 2000 | 2.27 |
| 11:50 ET | 100 | 2.2801 |
| 11:54 ET | 100 | 2.28 |
| 12:19 ET | 100 | 2.2822 |
| 12:21 ET | 100 | 2.3 |
| 12:35 ET | 210 | 2.28 |
| 01:06 ET | 200 | 2.2858 |
| 02:09 ET | 150 | 2.32 |
| 02:32 ET | 112 | 2.312 |
| 02:38 ET | 100 | 2.31 |
| 02:52 ET | 400 | 2.29 |
| 03:10 ET | 1043 | 2.27 |
| 03:19 ET | 1444 | 2.25 |
| 03:24 ET | 100 | 2.25 |
| 04:00 ET | 100 | 2.24 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lixte Biotechnology Holdings Inc | 5.0M | -0.7x | --- |
Blue Water Biotech Inc | 5.0M | -0.2x | --- |
Monopar Therapeutics Inc | 5.1M | -0.5x | --- |
Quoin Pharmaceuticals Ltd | 4.9M | -4,500.0x | --- |
GlucoTrack Inc | 5.2M | -0.8x | --- |
Windtree Therapeutics Inc | 4.7M | 0.0x | --- |
Company Information
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series consists of novel structures, which treat not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which has the potential to be effective in its class and may be useful for the treatment of chronic hereditary diseases.
Contact Information
- Headquarters
- No. 2, 248 Route 25AEAST SETAUKET, NY, United States 11733
- Phone
- 310-203-2902
- Fax
- 928-982-5050
Executives
- Chairman of the Board, President, Chief Executive Officer
- Bastiaan Van Der Baan
- Chief Financial Officer, Vice President
- Robert Weingarten
- Chief Operating Officer, Vice President
- Eric Forman
- Chief Medical Officer
- James Miser
- Independent Director
- Rene Bernards
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.39 |
EPS | $-3.29 |
Book Value | $3.10 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
